Return to search

NovImmune Raises $46m

NovImmune SA, a Geneva, Switzerland-based drug company focused on immune-related diseases, inflammation and organ transplantation, has raised CHF 58 million (approx. $46m) in Series B funding. BZ Bank and several of its clients led the deal, and was joined by Pictet Private Equity and return backers Lombard Odier Darier Hentsch, Novartis Venture Fund and Aravis Venture.